美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

亞盛醫藥

40.50

+1.924.97%

盤後：40.500.00000.00%16:10 EDT

成交量：1.17萬

成交額：47.36萬

市值：37.65億

市盈率：-55.06

高：41.14

開：40.98

低：39.91

收：38.58

52周最高：48.45

52周最低：16.50

股本：9,296.34萬

流通股本：7,158.28萬

量比：1.14

換手率：0.02%

股息：- -

股息率：- -

每股收益(TTM):-0.7356

每股收益(LYR):-0.7356

淨資產收益率：-159.65%

總資產收益率：-22.77%

市淨率：40.31

市盈率(LYR):-55.06

資料載入中...

總覽公司新聞公告

當3000億資金湧向18A新股

亞盛醫藥7月22日成交額為16.63萬美元

深耕的智慧：喧囂時代的生物醫藥“長期主義”

建国路128号

專訪亞盛醫藥董事長楊大俊：研發難成藥的靶點堪比登珠峯，做創新藥更應避免內卷

每日经济新闻

亞盛醫藥7月21日成交額為35.35萬美元

亞盛醫藥啃下“硬骨頭”，百億Bcl-2藥物市場格局生變

21世纪经济报道

亞盛醫藥7月17日成交額為22.96萬美元

早新聞｜我國發現新稀土礦物

首個國產原研！亞盛醫藥創新抗癌藥國內獲批上市，影響有多大？

亞盛醫藥再漲超7%近期配股淨籌超14.9億港元利沙托克拉新藥上市申請獲批

港股創新藥概念股午後持續走高！麗珠醫藥漲超13%，復星醫藥漲超8%

老虎资讯综合

港股異動 | 亞盛醫藥(06855)午前漲超4% 公司配股淨籌近15億港元加速商業化及創新藥研發

亞盛醫藥7月15日成交額為46.82萬美元

越疆折價配股合共淨籌約25億港元盤初股價均走低

亞盛醫藥擬配股籌資最多15.4億港元

中金：升亞盛醫藥-B(06855)目標價至88港元評級“跑贏行業”

亞盛醫藥利刃出鞘

【券商聚焦】東吳證券維持亞盛醫藥(06855)“買入”評級指公司未來收入增長較快海外市場潛力較大

聚焦細胞凋亡三十載，亞盛醫藥迎“價值躍遷”

聚焦細胞凋亡三十載，亞盛醫藥迎“價值躍遷”

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/AAPG/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AAPG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","market":"US","secType":"STK","nameCN":"亞盛醫藥","latestPrice":40.4987,"timestamp":1757102400000,"preClose":38.58,"halted":0,"volume":11693,"hourTrading":{"tag":"盘后","latestPrice":40.4987,"preClose":40.4987,"latestTime":"16:10 EDT","volume":79,"amount":3202.85,"timestamp":1757103004016},"delay":0,"floatShares":71582800,"shares":92963368,"eps":-0.735552,"marketStatus":"休市中","change":1.9187,"latestTime":"09-05 16:00:00 EDT","open":40.98,"high":41.135,"low":39.91,"amount":473616.9924,"amplitude":0.031752,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.735552,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1757318400000},"marketStatusCode":7,"adr":0,"adrRate":4,"listingDate":1737694800000,"exchange":"NASDAQ","adjPreClose":38.58,"preHourTrading":{"tag":"盘前","latestPrice":40.66,"preClose":38.29,"latestTime":"09:21 EDT","volume":770,"amount":31832.85182,"timestamp":1757078476206},"postHourTrading":{"tag":"盘后","latestPrice":40.4987,"preClose":40.4987,"latestTime":"16:10 EDT","volume":79,"amount":3202.85,"timestamp":1757103004016},"volumeRatio":1.136544779456076},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","floatShares":71582800,"roa":"-22.77%","roe":"-159.65%","lyrEps":-0.735552,"volumeRatio":1.136544779456076,"shares":92963368,"dividePrice":0,"high":41.135,"amplitude":0.031752,"preClose":38.58,"low":39.91,"week52Low":16.5,"pbRate":"40.31","psRate":"68.73","week52High":48.45,"institutionHeld":0,"latestPrice":40.4987,"eps":-0.735552,"divideRate":0,"volume":11693,"delay":0,"ttmEps":-0.735552,"open":40.98,"prevYearClose":17.25,"prevWeekClose":42.47,"prevMonthClose":42.47,"prevQuarterClose":39.375,"fiveDayClose":41.1327,"twentyDayClose":42.81,"sixtyDayClose":29.9},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AAPG\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-20","symbol":"AAPG","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"post","actualEps":null},{"date":"2025-03-27","symbol":"AAPG","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2024/12","expectedEps":null,"defaultRemindTime":1743062400000,"name":null,"time":"盤前","dateTimestamp":1743048000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AAPG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AAPG\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1743652800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AAPG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AAPG","date":"2025-09-05","current":-22.946281,"percent":0.993421,"low":-76.454813,"twenty":-59.664109,"median":-36.382297,"eighty":-31.979778,"high":-21.702816,"avg":-42.586735,"sd":14.167338,"marketCap":3724203040.4},"quantilePoints":[{"date":"2025-01-31","current":-29.751262,"twenty":-29.75286,"median":-29.751983,"eighty":-29.751262,"marketCap":1478269659.08},{"date":"2025-02-07","current":-32.664532,"twenty":-32.365221,"median":-31.242401,"eighty":-29.752127,"marketCap":1614694688.16},{"date":"2025-02-14","current":-31.1828,"twenty":-32.258438,"median":-31.212601,"eighty":-29.752938,"marketCap":1540476496.81},{"date":"2025-02-21","current":-36.382297,"twenty":-32.721933,"median":-31.802125,"eighty":-29.819279,"marketCap":1806628873.73},{"date":"2025-02-28","current":-33.43308,"twenty":-34.468465,"median":-32.375664,"eighty":-30.230932,"marketCap":1654638501.56},{"date":"2025-03-07","current":-34.452224,"twenty":-34.328072,"median":-32.712367,"eighty":-30.892818,"marketCap":1712841480.27},{"date":"2025-03-14","current":-33.065652,"twenty":-34.096417,"median":-32.760201,"eighty":-31.20664,"marketCap":1644428002.08},{"date":"2025-03-21","current":-32.72391,"twenty":-34.124503,"median":-32.947597,"eighty":-31.448698,"marketCap":1626713850.02},{"date":"2025-03-28","current":-33.955809,"twenty":-34.124503,"median":-33.010704,"eighty":-31.793328,"marketCap":1894714451.86},{"date":"2025-04-04","current":-35.921968,"twenty":-34.855052,"median":-33.21342,"eighty":-31.979778,"marketCap":2000185586.04},{"date":"2025-04-11","current":-29.511221,"twenty":-34.370118,"median":-33.010704,"eighty":-30.892818,"marketCap":1635879540.94},{"date":"2025-04-17","current":-29.520055,"twenty":-34.225935,"median":-32.760201,"eighty":-30.07059,"marketCap":1639709582.7},{"date":"2025-04-25","current":-41.553435,"twenty":-35.045268,"median":-32.920123,"eighty":-30.119556,"marketCap":2311372741.24},{"date":"2025-05-02","current":-38.492689,"twenty":-35.554336,"median":-33.187028,"eighty":-30.682879,"marketCap":2146245101.28},{"date":"2025-05-09","current":-37.35919,"twenty":-36.170996,"median":-33.361942,"eighty":-30.776099,"marketCap":2093177176.92},{"date":"2025-05-16","current":-35.007117,"twenty":-35.955639,"median":-33.43308,"eighty":-31.102567,"marketCap":1969122395.28},{"date":"2025-05-23","current":-39.338512,"twenty":-36.352488,"median":-33.608398,"eighty":-31.19472,"marketCap":2213435510.22},{"date":"2025-05-30","current":-38.856398,"twenty":-37.35919,"median":-33.992043,"eighty":-31.242401,"marketCap":2192363417.29},{"date":"2025-06-06","current":-42.814884,"twenty":-37.865895,"median":-34.141844,"eighty":-31.758144,"marketCap":2419987007.19},{"date":"2025-06-13","current":-48.171029,"twenty":-38.492689,"median":-34.477812,"eighty":-31.846105,"marketCap":2722575737.57},{"date":"2025-06-20","current":-55.929302,"twenty":-38.862859,"median":-34.635358,"eighty":-32.113451,"marketCap":3154688383.5},{"date":"2025-06-27","current":-59.787237,"twenty":-39.399619,"median":-35.123604,"eighty":-32.336589,"marketCap":3381751544.24},{"date":"2025-07-03","current":-64.068526,"twenty":-41.436089,"median":-35.258863,"eighty":-32.429915,"marketCap":3624015684.35},{"date":"2025-07-11","current":-59.084566,"twenty":-43.897892,"median":-35.501693,"eighty":-32.48435,"marketCap":3338745741.38},{"date":"2025-07-18","current":-61.880278,"twenty":-48.308604,"median":-35.791073,"eighty":-32.545465,"marketCap":3494679880.36},{"date":"2025-07-25","current":-58.315576,"twenty":-54.849764,"median":-35.921968,"eighty":-32.616809,"marketCap":3304687864.64},{"date":"2025-08-01","current":-60.559654,"twenty":-57.422661,"median":-36.233253,"eighty":-32.655768,"marketCap":3410643633.03},{"date":"2025-08-08","current":-69.260076,"twenty":-59.023969,"median":-36.597865,"eighty":-32.679287,"marketCap":3910472388.03},{"date":"2025-08-15","current":-72.346957,"twenty":-59.602544,"median":-37.391167,"eighty":-32.709995,"marketCap":4086922647.44},{"date":"2025-08-22","current":-26.724459,"twenty":-60.097702,"median":-37.493155,"eighty":-32.679287,"marketCap":4314209810.62},{"date":"2025-08-29","current":-24.396919,"twenty":-59.865528,"median":-36.699167,"eighty":-32.48435,"marketCap":3966417985.85},{"date":"2025-09-05","current":-22.946281,"twenty":-59.664109,"median":-36.382297,"eighty":-31.979778,"marketCap":3724203040.4}],"updateTime":1757259191660},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AAPG\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2553917788","title":"當3000億資金湧向18A新股","url":"https://stock-news.laohu8.com/highlight/detail?id=2553917788","media":"氨基观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553917788?lang=zh_tw&edition=fundamental","pubTime":"2025-07-24 19:58","pubTimestamp":1753358280,"startTime":"0","endTime":"0","summary":"7月22日维立志博完成认购，数据显示其融资申购金额飙至惊人的3300亿港元，散户认购倍数超3000倍。目前其暗盘交易显示，股价已经大涨超过90%，总市值超130亿港元。/ 02 /成功样本港股18A新股受追捧的盛况，并非始于维立志博。二级市场融资渠道已显著畅通：截至目前，已有10家药企完成IPO，募资总额逼近200亿港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724203654a46157fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724203654a46157fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06855","09606","ONC","01177","01530","BK0239","01167","09926","LU1064130708.USD","01228","688506","09995","LU2488822045.USD","688235","688331","LU2148510915.USD","LEGN","AAPG","06160","02616","LU1064131003.USD","SBHMY","01952"],"gpt_icon":0},{"id":"2553262193","title":"亞盛醫藥7月22日成交額為16.63萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553262193","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553262193?lang=zh_tw&edition=fundamental","pubTime":"2025-07-23 09:15","pubTimestamp":1753233315,"startTime":"0","endTime":"0","summary":"美东时间2025年7月22日，亚盛医药成交额为16.63万美元，成交额较昨日减少52.96%，当日成交量为4227.00股。亚盛医药于2025年7月22日跌0.81%，报39.39美元，该股过去5个交易日涨7.15%，年初至今涨128.35%，过去60日涨54.47%。公司专注于开发抑制蛋白质相互作用以恢复细胞凋亡或程序性细胞死亡的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723091522a45d82bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723091522a45d82bb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2553238335","title":"深耕的智慧：喧囂時代的生物醫藥“長期主義”","url":"https://stock-news.laohu8.com/highlight/detail?id=2553238335","media":"建国路128号","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553238335?lang=zh_tw&edition=fundamental","pubTime":"2025-07-22 15:11","pubTimestamp":1753168265,"startTime":"0","endTime":"0","summary":"而之所以在二级市场仍旧出圈，这背后折射出的，大概是其在喧嚣与浮躁中坚守“长期主义”的内在价值开始被市场重新发现和定价。放眼全球，丹麦的诺和诺德便是“长期主义”最完美的诠释者。图|诺和诺德股价走势图将目光转回国内，一批优秀的本土创新药企同样通过“长期主义”的践行，迎来了属于自己的高光时刻。最后，一家优秀的“长期主义”公司，其成功绝非依赖单一产品，而是一个整体性、连续性的系统。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722151356a6ba16f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722151356a6ba16f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DDC","688176","IE00BKVL7J92.USD","688235","06160","BK4532","LU1093756325.SGD","NVO","06855","BK4588","BK4212","AAPG","IE00BZ1G4Q59.USD","LU1093756168.USD","BK4007","BK4585","BK4599","ONC","LU0154236417.USD"],"gpt_icon":1},{"id":"2553289026","title":"專訪亞盛醫藥董事長楊大俊：研發難成藥的靶點堪比登珠峯，做創新藥更應避免內卷","url":"https://stock-news.laohu8.com/highlight/detail?id=2553289026","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553289026?lang=zh_tw&edition=fundamental","pubTime":"2025-07-22 12:54","pubTimestamp":1753160095,"startTime":"0","endTime":"0","summary":"亚盛医药董事长、CEO杨大俊在接受《每日经济新闻》记者采访时说。今年7月，亚盛医药的利沙托克拉（利生妥）获得国家药品监督管理局附条件批准上市，成为国产原研首家、全球第2款Bcl-2抑制剂，打破了艾伯维在这一领域长达9年的垄断。做创新药更应避免内卷在Bcl-2靶点的研究上，杨大俊是幸运的，亚盛医药率先打破艾伯维的垄断“僵局”，是中国创新药成果的一次验证。对此，杨大俊直言，当下创新药“内卷”的症结，源于两个深层原因。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722125535954c5129&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722125535954c5129&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ASPHF","BK4139","AAPG"],"gpt_icon":0},{"id":"2553675400","title":"亞盛醫藥7月21日成交額為35.35萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553675400","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553675400?lang=zh_tw&edition=fundamental","pubTime":"2025-07-22 09:15","pubTimestamp":1753146914,"startTime":"0","endTime":"0","summary":"美东时间2025年7月21日，亚盛医药成交额为35.35万美元，成交额较昨日增加22.04%，当日成交量为8878.00股。亚盛医药于2025年7月21日跌1.68%，报39.71美元，该股过去5个交易日涨9.7%，年初至今涨130.2%，过去60日涨66.15%。公司专注于开发抑制蛋白质相互作用以恢复细胞凋亡或程序性细胞死亡的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722091530a45adaaa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722091530a45adaaa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2552545501","title":"亞盛醫藥啃下“硬骨頭”，百億Bcl-2藥物市場格局生變","url":"https://stock-news.laohu8.com/highlight/detail?id=2552545501","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552545501?lang=zh_tw&edition=fundamental","pubTime":"2025-07-18 10:45","pubTimestamp":1752806700,"startTime":"0","endTime":"0","summary":"一款中国原创药物，打破了跨国药企近十年的垄断，彻底改写了全球抗癌药市场的竞争格局。近日，创新药企亚盛医药（纳斯达克代码：AAPG；香港联交所代码：6855）宣布，公司自主研发的新型Bcl-2选择性抑制剂利生妥?（通用名：利沙托克拉；研发代码：APG-2575）获中国国家药品监督管理局（NMPA）批准附条件上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202507183460886641.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202507183460886641.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2552458739","title":"亞盛醫藥7月17日成交額為22.96萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2552458739","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552458739?lang=zh_tw&edition=fundamental","pubTime":"2025-07-18 09:15","pubTimestamp":1752801314,"startTime":"0","endTime":"0","summary":"美东时间2025年7月17日，亚盛医药成交额为22.96万美元，成交额较昨日减少51.43%，当日成交量为5812.00股。亚盛医药于2025年7月17日涨2.59%，报39.62美元，该股过去5个交易日跌2.75%，年初至今涨129.68%，过去60日涨107.22%。公司专注于开发抑制蛋白质相互作用以恢复细胞凋亡或程序性细胞死亡的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718091528a452215d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718091528a452215d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2552543753","title":"早新聞｜我國發現新稀土礦物","url":"https://stock-news.laohu8.com/highlight/detail?id=2552543753","media":"e公司","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552543753?lang=zh_tw&edition=fundamental","pubTime":"2025-07-18 07:50","pubTimestamp":1752796200,"startTime":"0","endTime":"0","summary":"我国自研创新药列入世卫组织儿童药物优化优先清单近日，我国自主研发的、抗呼吸道合胞病毒的创新药——齐瑞索韦列入世界卫生组织儿童药物优化优先清单，有望为全球儿童带来可及、可负担的有效治疗。该药是首个在中国发明、开发并拓展到全球的儿童创新药。截至目前，公司已有2个创新药项目获批上市，多个创新药项目处于临床试验阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718075132a6b0ac60&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718075132a6b0ac60&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK1161","BK1574","688012","688567","688072","06855"],"gpt_icon":0},{"id":"2552688105","title":"首個國產原研！亞盛醫藥創新抗癌藥國內獲批上市，影響有多大？","url":"https://stock-news.laohu8.com/highlight/detail?id=2552688105","media":"澎湃新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552688105?lang=zh_tw&edition=fundamental","pubTime":"2025-07-17 14:02","pubTimestamp":1752732157,"startTime":"0","endTime":"0","summary":"Bcl-2抑制剂可特异性地结合并抑制Bcl-2蛋白，有效恢复肿瘤细胞的凋亡通路，诱导癌细胞死亡。此次中国原创、全球创新的药物有望改写全球Bcl-2抑制剂市场的竞争格局。利沙托克拉是亚盛医药第二个获批上市、进入商业化阶段的原创新药，未来是否也会考虑BD？亚盛医药目前已经有两款产品获批，“我们希望2027年做到收支平衡有利润”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071714035797a95af1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071714035797a95af1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06855","BK4139","AAPG"],"gpt_icon":0},{"id":"2552725281","title":"亞盛醫藥再漲超7%近期配股淨籌超14.9億港元利沙托克拉新藥上市申請獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2552725281","media":"动脉网","labels":["shareholding","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552725281?lang=zh_tw&edition=fundamental","pubTime":"2025-07-17 10:06","pubTimestamp":1752717960,"startTime":"0","endTime":"0","summary":"亚盛医药-B股价涨超7%，配股筹14.93亿港元，新药利沙托克拉上市填补国内空白，全球商业化潜力大，有望成第二款获批的BCL-2抑制剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071710152197a92516&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071710152197a92516&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ASPHF","AAPG"],"gpt_icon":0},{"id":"1110572086","title":"港股創新藥概念股午後持續走高！麗珠醫藥漲超13%，復星醫藥漲超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1110572086","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110572086?lang=zh_tw&edition=fundamental","pubTime":"2025-07-16 13:39","pubTimestamp":1752644353,"startTime":"0","endTime":"0","summary":"7月16日，港股创新药概念股午后持续走高，$丽珠医药(01513)$涨超13%，$复星医药(02196)$涨超8%，$绿叶制药(02186)$涨超7%，$康方生物(09926)$涨近6%，$东阳光长江药业(01558)$、$亚盛医药-B(06855)$涨超4%。","market":"hk","thumbnail":"https://static.tigerbbs.com/c1cb237e736a4e03c939622e7b71e8e7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/c1cb237e736a4e03c939622e7b71e8e7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"4e7834c15c47c74e9bfd4d734ca81974","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1606","09926","HSCEI","02196","06978","IE00B5MMRT66.SGD","LU1720050803.USD","LU0417516571.SGD","02186","HSTECH","01558","BK4139","IE00B543WZ88.USD","BK1515","01513","AAPG","BK1574","BK4614","07226","YANG"],"gpt_icon":0},{"id":"2551111185","title":"港股異動 | 亞盛醫藥(06855)午前漲超4% 公司配股淨籌近15億港元 加速商業化及創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2551111185","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551111185?lang=zh_tw&edition=fundamental","pubTime":"2025-07-16 11:54","pubTimestamp":1752638052,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，亚盛医药午前涨超4%，截至发稿，涨4.11%，报74.75港元，成交额4.95亿港元。消息面上，亚盛医药近日宣布，拟按每股68.60港元的价格发行最多2200万股新股，配售事项所得净额约为14.93亿港元。董事认为，配售事项及认购事项将进一步巩固本集团的财务状况，并为本集团提供额外营运资金。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"4e7834c15c47c74e9bfd4d734ca81974","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1318372.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK4139","AAPG","BK1161","159992","06855","06978"],"gpt_icon":0},{"id":"2551113161","title":"亞盛醫藥7月15日成交額為46.82萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551113161","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551113161?lang=zh_tw&edition=fundamental","pubTime":"2025-07-16 09:15","pubTimestamp":1752628515,"startTime":"0","endTime":"0","summary":"美东时间2025年7月15日，亚盛医药成交额为46.82万美元，成交额较昨日减少25.17%，当日成交量为1.26万股。亚盛医药于2025年7月15日涨1.55%，报36.76美元，该股过去5个交易日跌11.1%，年初至今涨113.1%，过去60日涨94.81%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-07-15|46.82万|-25.17%|1.26万|#|2025-07-14|62.56万|157.41%|1.72万|#|2025-07-11|24.30万|-66.18%|6315.00|#|2025-07-10|71.87万|240.51%|1.75万|#|2025-07-09|21.11万|-57.18%|5040.00|亚盛医药集团是一家临床阶段的生物技术公司，从事癌症、乙型肝炎病毒和某些年龄相关疾病的新型小规模疗法的开发和销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716091531a44d6980&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716091531a44d6980&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2551132119","title":"越疆折價配股合共淨籌約25億港元 盤初股價均走低","url":"https://stock-news.laohu8.com/highlight/detail?id=2551132119","media":"金吾资讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551132119?lang=zh_tw&edition=fundamental","pubTime":"2025-07-15 09:48","pubTimestamp":1752544097,"startTime":"0","endTime":"0","summary":"金吾财讯 | 越疆 及亚盛医药均折价配股抽水，合共净筹约25亿港元，盘初股价均走低。截至发稿，越疆报58.3港元，跌2.83%，成交额5718.93万港元；亚盛医药报71.7港元，跌4.02%，成交额19.13亿港元。公司有90日禁售承诺。亚盛医药宣布，拟先旧后新配售最多2200万股新股份，占扩大后的已发行股本约5.92%，每股配售价为68.6港元，较上交易日收市价74.7港元折让约8.17%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071509485097a65f98&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071509485097a65f98&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","06855","AAPG"],"gpt_icon":0},{"id":"2551188991","title":"亞盛醫藥擬配股籌資最多15.4億港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551188991","media":"DoNews","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551188991?lang=zh_tw&edition=fundamental","pubTime":"2025-07-14 19:13","pubTimestamp":1752491583,"startTime":"0","endTime":"0","summary":"2025年7月14日，交易文件显示，亚盛医药计划通过先旧后新方式配售股份，预计筹资至多15.4亿港元（约1.96亿美元）。公司拟配售2,200万股股份，每股配售价在68.35至70港元之间，较上周一收盘价74.70港元折让6.3%-8.5%。此次配股旨在增强公司资金流动性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714191420954206e8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714191420954206e8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06855","BK4139","ASPHF","AAPG"],"gpt_icon":0},{"id":"2551920501","title":"中金：升亞盛醫藥-B(06855)目標價至88港元 評級“跑贏行業”","url":"https://stock-news.laohu8.com/highlight/detail?id=2551920501","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551920501?lang=zh_tw&edition=fundamental","pubTime":"2025-07-14 10:04","pubTimestamp":1752458674,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，考虑到利生妥获批上市及全球适应症拓展前景，维持亚盛医药-B跑赢行业评级，根据DCF模型，上调目标价27.5%至88港币，较当前股价有15.3%的上行空间。根据公司公告，此前，中国尚未有Bcl-2抑制剂获批用于治疗CLL/SLL，全球也仅艾伯维的维奈克拉获批上市。该行认为利生妥的获批上市有望为国内CLL/SLL后线患者带来新的治疗选择，建议关注后续商业化为公司业绩带来的增量。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1317167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06855","AAPG"],"gpt_icon":0},{"id":"2551927949","title":"亞盛醫藥利刃出鞘","url":"https://stock-news.laohu8.com/highlight/detail?id=2551927949","media":"药智网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551927949?lang=zh_tw&edition=fundamental","pubTime":"2025-07-14 09:43","pubTimestamp":1752457417,"startTime":"0","endTime":"0","summary":"近日，根据NMPA官网的消息，亚盛医药万众期待的管线利沙托克拉片已附条件批准上市，用于既往经过至少包含布鲁顿酪氨酸激酶抑制剂在内的一种系统治疗的成人慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者。利刃出鞘维奈克拉上市之后，近十年之久无后来者，而直到如今，第二款药物——利沙托克拉片才获批上市。亚盛医药的后备军作为一家目前市值已经较高的biotech，亚盛医药肯定不止奥雷巴替尼和APG-2575两个大单品支撑，后面肯定还有生力军。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714094538a6a78424&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714094538a6a78424&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06855","AAPG","BK1574","ASPHF"],"gpt_icon":0},{"id":"2551492427","title":"【券商聚焦】東吳證券維持亞盛醫藥(06855)“買入”評級 指公司未來收入增長較快 海外市場潛力較大","url":"https://stock-news.laohu8.com/highlight/detail?id=2551492427","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551492427?lang=zh_tw&edition=fundamental","pubTime":"2025-07-14 09:18","pubTimestamp":1752455905,"startTime":"0","endTime":"0","summary":"APG-2575在国内的获批有望助力期未来的潜在对外授权落地，全球销售分成将为公司贡献更多收入，潜力值得期待。公司未来收入增长较快，确定性高，海外市场潜力较大，维持“买入”评级。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1962132","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855","AAPG","601555"],"gpt_icon":0},{"id":"2551290509","title":"聚焦細胞凋亡三十載，亞盛醫藥迎“價值躍遷”","url":"https://stock-news.laohu8.com/highlight/detail?id=2551290509","media":"医曜","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551290509?lang=zh_tw&edition=fundamental","pubTime":"2025-07-14 08:25","pubTimestamp":1752452714,"startTime":"0","endTime":"0","summary":"千呼万唤始出来，亚盛医药的第二颗“重磅炸弹”利生妥终于落地。这背后的原因正是深耕细胞凋亡赛道二十载所引发的“进化”。利生妥则已经于2025年7月10日获批上市，成为中国首款自主研发、全球第二款Bcl-2抑制剂。作为这一靶点最早的布局者，亚盛医药靠“三十年，三款药”的坚持，用一次又一次的失败才最终看到了“胜利的大门”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714082841a6a76164&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714082841a6a76164&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06855","AAPG","BK1161","BK1574"],"gpt_icon":0},{"id":"2551153924","title":"聚焦細胞凋亡三十載，亞盛醫藥迎“價值躍遷”","url":"https://stock-news.laohu8.com/highlight/detail?id=2551153924","media":"医曜","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551153924?lang=zh_tw&edition=fundamental","pubTime":"2025-07-14 08:25","pubTimestamp":1752452700,"startTime":"0","endTime":"0","summary":"千呼万唤始出来，亚盛医药的第二颗“重磅炸弹”利生妥终于落地。这背后的原因正是深耕细胞凋亡赛道二十载所引发的“进化”。利生妥则已经于2025年7月10日获批上市，成为中国首款自主研发、全球第二款Bcl-2抑制剂。作为这一靶点最早的布局者，亚盛医药靠“三十年，三款药”的坚持，用一次又一次的失败才最终看到了“胜利的大门”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714091629a4489865&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714091629a4489865&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ASPHF","AAPG","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":3,"totalSize":177,"code":"91000000","status":"200"}]}}